- Home
- WBX vs CHRS Comparison
WBX vs CHRS Comparison
Compare WBX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- CHRS
- Stock Information
- Founded
- WBX 2015
- CHRS 2010
- Country
- WBX Spain
- CHRS United States
- Employees
- WBX N/A
- CHRS N/A
- Industry
- WBX Industrial Specialties
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WBX Consumer Discretionary
- CHRS Health Care
- Exchange
- WBX Nasdaq
- CHRS Nasdaq
- Market Cap
- WBX 102.7M
- CHRS 84.2M
- IPO Year
- WBX N/A
- CHRS 2014
- Fundamental
- Price
- WBX $6.00
- CHRS $0.82
- Analyst Decision
- WBX Buy
- CHRS Buy
- Analyst Count
- WBX 3
- CHRS 3
- Target Price
- WBX $0.72
- CHRS $4.68
- AVG Volume (30 Days)
- WBX 26.4K
- CHRS 1.3M
- Earning Date
- WBX 07-31-2025
- CHRS 08-07-2025
- Dividend Yield
- WBX N/A
- CHRS N/A
- EPS Growth
- WBX N/A
- CHRS N/A
- EPS
- WBX N/A
- CHRS N/A
- Revenue
- WBX $171,352,140.00
- CHRS $272,251,000.00
- Revenue This Year
- WBX N/A
- CHRS N/A
- Revenue Next Year
- WBX $44.10
- CHRS $106.56
- P/E Ratio
- WBX N/A
- CHRS $1.90
- Revenue Growth
- WBX 3.75
- CHRS 19.87
- 52 Week Low
- WBX $4.60
- CHRS $0.66
- 52 Week High
- WBX $32.80
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- WBX 36.26
- CHRS 53.65
- Support Level
- WBX $6.10
- CHRS $0.72
- Resistance Level
- WBX $6.36
- CHRS $0.77
- Average True Range (ATR)
- WBX 0.67
- CHRS 0.04
- MACD
- WBX -0.06
- CHRS 0.01
- Stochastic Oscillator
- WBX 42.41
- CHRS 91.74
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates smart charging system combining technology design that manages the communication between user, vehicle, grid, building, and charger. The company is engaged in designing, manufacturing, and distributing faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA) which is also its key revenue generating segment, North America, and Asia‑Pacific.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.